Market Overview

UPDATE: Deutsche Bank Raises PT to $95 on Gilead Sciences on Latest Data

Share:
Related GILD
Gilead Gets European CHMP's Positive Opinion For Epclusa For All Genotypes of Chronic Hepatitis C Treatment
Could Rally Cool Off Ahead Of Friday's GDP Data and Yellen Speech?
Gilead's Profits Won't Disappear Overnight (Seeking Alpha)

Deutsche Bank reiterated its Buy rating on Gilead Sciences (NASDAQ: GILD) and increased its price target from $75 to $95.

Deutsche Bank said, "At the liver meeting today, Bristol ns5a and GILD nuke showed 100pct SVR with or without ribavirin, in patients that showed up for follow-up. So far 68/82 patients are at SVR12 timeframe and it was noted all 68 were undetectable. While Bristol and Abbott also have regimens with high cure rates, they require more pills (3 drug DAA) and likely will require ribavirin."

Gilead Sciences closed at $73.92 on Monday.

Latest Ratings for GILD

DateFirmActionFromTo
May 2016Morgan StanleyMaintainsEqual-weight
Apr 2016CitigroupMaintainsBuy
Apr 2016Maxim GroupDowngradesBuyHold

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (GILD)

View Comments and Join the Discussion!